PHS
KERX

PFM Health Sciences’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

PFM Health Sciences’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-97,687
Closed -$344K – 92
2015
Q3 		$344K Buy
+97,687
New +$654K 0.01% 70

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PFM Health Sciences's KERX Position: Q4 2015 in Review

PFM Health Sciences sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 97,687 shares — an estimated $344K sold.

PFM Health Sciences first reported a position in KERX in Q3 2015 and held it in 1 quarter. The position peaked at $344K in Q3 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • PFM Health Sciences reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • PFM Health Sciences sold 97,687 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $344K.
  • PFM Health Sciences first reported a position in Keryx Biopharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • PFM Health Sciences's Keryx Biopharmaceuticals Inc position peaked at $344K in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on PFM Health Sciences's 13F filing for Q4 2015, filed 16 Feb 2016.